Christopher J Record,Mariola Skorupinska,Matilde Laura,Alexander M Rossor,Davide Pareyson,Chiara Pisciotta,Shawna M E Feely,Thomas E Lloyd,Rita Horvath,Reza Sadjadi,David N Herrmann,Jun Li,David Walk,Sabrina W Yum,Richard A Lewis,John Day,Joshua Burns,Richard S Finkel,Mario A Saporta,Sindhu Ramchandren,Michael D Weiss,Gyula Acsadi,Vera Fridman,Francesco Muntoni,Roy Poh,James M Polke,Stephan Zuchner,Michael E Shy,Steven S Scherer,Mary M Reilly,Lisa Abreu,Kimberly A Anderson,Silvia Baratta,Debbie Berry,Julian Blake,Eleonora Cavalca,Kayla Cornett,Andrea Cortese,Gabrielle Donlevy,Amanda Dragon,Magdalena Dudziec,Katy Eichinger Tim Estilow,Valerie Ferment,Natalie Grant,Tiffany Grider,Emily Hyslop,Tara Jones,Nicole Kressin,Wendy Leon,Stefania Magri,Brett McCray,Manoj Menezes,Evelin Milev,Lindsey Parrott,Pooja Patel,Cláudia Brito Pires,Valeria Prada,Gita Ramdharry,Paola Saveri,Giulia Schirinzi,Rosemary Shy,Carly Siskind,Janet Sowden,Sydney Stork,Charlotte J Sumner,Franco Taroni,Simone Thomas,Jennifer Twachtman-Bassett,Nidia Villalpando,Dragan Vujovic,Julie Wells,Elizabeth Wood,Riccardo Zuccarino,for the Inherited Neuropathies Consortium - Rare Disease Clinical Research Network

Abstract:Charcot-Marie-Tooth disease (CMT) due to GJB1 variants (CMTX1) is the second most common form of CMT. It is an X-linked disorder characterised by progressive sensory and motor neuropathy with males affected more severely than females. Many reported GJB1 variants remain classified as variants of uncertain significance (VUS). In this large, international, multicentre study we prospectively collected demographic, clinical and genetic data on patients with CMT associated with GJB1 variants. Pathogenicity for each variant was defined using adapted American College of Medical Genetics criteria. Baseline and longitudinal analyses were conducted to study genotype-phenotype correlations, to calculate longitudinal change using the CMT Examination Score (CMTES), to compare males versus females, and pathogenic/likely pathogenic (P/LP) variants versus VUS. We present 387 patients from 295 families harbouring 154 variants in GJB1 . Of these, 319 patients (82.4%) were deemed to have P/LP variants, 65 had VUS (16.8%) and 3 benign variants (0.8%; excluded from analysis); an increased proportion of patients with P/LP variants compared with using ClinVar's classification (74.6%). Male patients (166/319, 52.0%, P/LP only) were more severely affected at baseline. Baseline measures in patients with P/LP variants and VUS showed no significant differences, and regression analysis suggested the disease groups were near identical at baseline. Genotype-phenotype analysis suggested c.-17G>A produces the most severe phenotype of the five most common variants, and missense variants in the intracellular domain are less severe than other domains. Progression of disease was seen with increasing CMTES over time up to 8 years follow-up. Standard response mean (SRM), a measure of outcome responsiveness, peaked at 3 years with moderate responsiveness (change in CMTES (ΔCMTES) = 1.3 ± 2.6, p = 0.00016, SRM = 0.50). Males and females progressed similarly up to 8 years, but baseline regression analysis suggested that over a longer period, females progress more slowly. Progression was most pronounced for mild phenotypes (CMTES = 0-7; 3-year ΔCMTES = 2.3 ± 2.5, p = 0.001, SRM = 0.90). Enhanced variant interpretation has yielded an increased proportion of GJB1 variants classified as P/LP and will aid future variant interpretation in this gene. Baseline and longitudinal analysis of this large cohort of CMTX1 patients describes the natural history of the disease including the rate of progression; CMTES showed moderate responsiveness for the whole group at 3 years and higher responsiveness for the mild group at 3, 4 and 5 years. These results have implications for patient selection for upcoming clinical trials.

Expanding the Clinical Spectrum of DRP2 -Associated Charcot-Marie-Tooth Disease

[A Genotyping Study of 13 Cases of Early-Onset Charcot-Marie-Tooth Disease].

The Clinical Features in Patients with Charcot-Marie-Tooth with PMP22 Duplication

Clinical,pathological and Genetic Studies in a Chinese Charcot-Marie-Tooth Disease Type 2 Family

Neuropilin 1 sequestration by neuropathogenic mutant glycyl-tRNA synthetase is permissive to vascular homeostasis

Natural history of Charcot-Marie-Tooth disease type 2A: a large international multicentre study

Neuropathy due to bi-allelic SH3TC2 variants: Genotype-phenotype correlation and natural history

Assessment of Targeted Next-Generation Sequencing as a Tool for the Diagnosis of Charcot-Marie-Tooth Disease and Hereditary Motor Neuropathy

Genetic approaches and pathogenic pathways in the clinical management of Charcot-Marie-Tooth disease

A study concept of expeditious clinical enrollment for genetic modifier studies in Charcot–Marie–Tooth neuropathy 1A

Insights into phenotypic variability caused by GARS1 pathogenic variants

One Multilocus Genomic Variation Is Responsible for a Severe Charcot-Marie-Tooth Axonal Form

Mild Late-Onset Sensory Neuropathy Associated with Heterozygous Missense GDAP1 Variants

Biallelic variants in ARHGAP19 cause a motor-predominant neuropathy with asymmetry and conduction slowing

Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease

Genetic analysis and natural history of Charcot-Marie-Tooth disease CMTX1 due to GJB1 variants

A Novel Missense Mutation in Peripheral Myelin Protein-22 Causes Charcot-Marie-Tooth Disease

Charcot-Marie-Tooth disease secondary to biallelic mutations in SORD

[Guidelines for molecular diagnosis of Charcot-Marie-Tooth disease]

Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease

Dominant mutations in ITPR3 cause Charcot-Marie-Tooth disease